Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A prospective study

Abstract

Objectives: To investigate the benefit of α1‐adrenoceptor antagonist naftopidil on the quality of life (QOL) of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS). Methods: A total of 99 men with BPH/LUTS were prospectively recruited. The Short Form‐8 (SF‐8) was used for generic QOL assessment and each parameter was compared with the norm in these patients. Longitudinal changes were evaluated using the SF‐8 and the International Prostatic Symptoms Score (I‐PSS) at baseline, 4 and 8 weeks after naftopidil administration. The relationship between SF‐8 and I‐PSS was analyzed. Results: Five of eight components in the SF‐8 were significantly lower than the Japanese national norm at baseline. SF‐8 score was improved by naftopidil at 4 and 8 weeks in general health (GH) and physical component summary (PCS) in the patients in their 70s. Mental health (MH) and mental component summary (MCS) were improved at 8 weeks in patients in their 60s. When analyzing the whole cohort, SF‐8 GH, role emotional (RE) and MH had improved at 8 weeks, which was similar to the norm, and bodily pain (BP) results were better. Compared with the baseline, total I‐PSS, storage/voiding symptoms and QOL index scores improved significantly under naftopidil. Each component of I‐PSS (except for hesitancy) correlated with SF‐8 sub‐scales (except for BP) to some extent. Conclusions: BPH/LUTS impairs generic QOL, which is improved by naftopidil treatment. SF‐8 can be a useful instrument to assess the efficacy of BPH/LUTS treatment because its simplicity to complete and analyze, and its meaningful relationship to I‐PSS.

Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study

“…Effectiveness of naftopidil at a high dose for voiding symptoms can be explained by pharmacokinetics/pharmacodynamics of the agent in vivo and its effect on α 1 -adrenoceptor antagonists/ α 1 -adrenoreceptors interaction [13]. Storage symptoms are considered to represent those of BPH-related overactive bladder [14], and most recent basic studies on α 1 -adrenoceptor antagonists/ α 1 -adrenoreceptors in the lower urinary tract may account for the dose-dependent efficacy of naftopidil for improving storage symptoms [14, 15]. Unfortunately, our study cannot clarify the reason for improved storage symptoms including nocturia with naftopidil; the complexity of the mechanism of nocturia made us refrain from explicating this phenomenon [16].…”

Naftopidil for the treatment of benign prostate hyperplasia: a systematic review

“…A previous study 39 , focusing on health-related QoL (HRQoL), described significant improvement of IPSS and King's Health Questionnaire Score domains after 12 weeks of treatment with naftopidil, particularly for patients with overactive bladder. A recent study of Komiya and colleagues 40 …”

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia

“…Komiya et al demonstrated that LUTS/BPH impaired generic QOL evaluated by the Short Form-8 (SF-8), that was improved by naftopidil treatment 58. Awa et al showed that naftopidil significantly improved 7 domains, though not general health perceptions and social limitations, in the King’s Health Questionnaire (KHQ) having 9 domains consisting of 21 questions 59…”